ERBB2 and breast carcinoma: The human HER2+++ breast cancer cell line BT-474 was used as a positive control of sensitivity to anti-HER2 drugs, as this cell line is extensively employed to study cellular growth and signaling responses to HER2-targeted therapies (Stuhlmi et al., 2015; Brockhoff et al., 2007).